Equivalence of Immunological Response to COVID-19 Vaccination in Prostate Cancer Patients

Abstract

Objectives: To elucidate antibody responses to COVID-19 (coronavirus disease 2019) vaccination among patients with Prostate cancer (Pca), group comparisons between patients with Pca and healthy controls were conducted at several times points after COVID-19 vaccination. Methods: Blood samples from 19 consecutive patients and 12 healthy controls were prospectively collected before first vaccination, and at 1, 3, and 6 months after first vaccination. BNT 162b2 (Pfizer/BioNTech) vaccines were administered for all patients with Pca. Antibody titers were determined by enzyme-linked immunosorbent assay using recombinant protein of the SARSCoV- 2 spike-protein receptor-binding domain as an antigen. Results: Mean age was significantly higher for patients (73.6±9.7 years) than for controls (63.2±3.4 years; P<0.01). Mean initial PSA for the overall cohort was 330±615 ng/mL. Ten patients had localized Pca and 9 patients had metastatic Pca. ADT was administered for the 84% (16/19) patients. Treatment with ADT and/or Androgen Receptor-Axis-Targeted (ARAT) agent had been continuously performed in 68% (13/19) patients since the first vaccination. After the first vaccination, antibody titer was significantly increased at 1 month after vaccination and then gradually declined over time in each group. Regarding the comparison between the two groups, mean antibody titer was not significantly different in patients during the observational period. Conclusions: This is a first report from an Eastern country to find that immunological response to first COVID-19 vaccination was equivalent in patients with Pca compared with healthy controls.